LivaNova (LIVN) Stock Forecast & Price Target
$4.50B
Market Cap
23.45
P/E
18.82
Forward P/E
—
Score
LIVN price $81.99 +1.33 +1.65%
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1213900000 | 1012300000 | 1107000000 | 1084170000 | 934241000 | 1035365000 | 1021805000 | 1153545000 | 1253437000 | 1388100000 |
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an…
Consensus Buy from 15 analysts. Average price target $93.33, +13.8% versus the current price. Low $85.00. High $105.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $93.33 for LivaNova (LIVN), 13.8% above the current price of $81.99. Of 15 analysts covering the stock, 11 rate it Buy or Strong Buy, 3 Hold, and 1 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $85.00 |
|---|---|
| Average | $93.33 |
| High | $105.00 |
The average is 13.8% above the current price of $81.99.
Of 15 analysts, 11 rate LivaNova Buy or Strong Buy, 3 Hold, and 1 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Analyst averages on file: 2026, EPS $4.36, revenue $1.52 billion. 2027, EPS $4.68, revenue $1.63 billion.
The Stocklytics Score, when it is published for LIVN, averages value, quality, and growth on a 0–100 scale. It is not a price target. Fair value is a separate estimate on the fair value tab.
$93.33 average, with a published range of $85.00 to $105.00.
The consensus is Buy from 15 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is $4.36. The average revenue estimate is $1.52 billion.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: LivaNova · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$4.50B
Market Cap
23.45
P/E
18.82
Forward P/E
—
Score